MAD2L2: A protein with potential as a drug target or biomarker

Target Name: MAD2L2

NCBI ID: G10459

MAD2L2

MAD2L2: A protein with potential as a drug target or biomarker

MAD2L2, also known as OTTHUMP00000002278, is a protein that is expressed in various tissues throughout the body. It is a key regulator of mitochondrial fusion and has been implicated in a number of cellular processes, including cell division, apoptosis, and metabolism.

In recent years, researchers have been increasingly interested in MAD2L2 as a potential drug target or biomarker. This is because the regulation of mitochondrial fusion and metabolism is a critical aspect of cellular function, and alterations in these processes have been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

One of the reasons for the growing interest in MAD2L2 is its role in the regulation of mitochondrial fusion. Mitochondria are organelles that are responsible for generating the energy that cells require for their basic life functions, and they are essential for the survival of all cells. Mitochondrial fusion is the process by which two mitochondria fuse together to form a single mitochondria, and this process is critical for the growth and development of new cells. MAD2L2 has been shown to play a key role in regulating the fusion of mitochondria, and researchers are investigating its potential as a drug target or biomarker.

In addition to its role in mitochondrial fusion, MAD2L2 has also been shown to be involved in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. Apoptosis is a natural and essential aspect of cell life, and it is involved in the removal of damaged or dysfunctional cells, as well as the removal of duplicated or unnecessary cells. MAD2L2 has been shown to play a key role in regulating apoptosis, and researchers are investigating its potential as a drug target or biomarker.

MAD2L2 has also been shown to be involved in the regulation of metabolism, which is the process by which cells convert the energy and nutrients they need to maintain their basic life functions. MAD2L2 has also been shown to play a key role in regulating metabolism, and researchers are investigating its potential as a drug target or biomarker.

In conclusion, MAD2L2 is a protein that is expressed in various tissues throughout the body and is involved in the regulation of mitochondrial fusion, apoptosis, and metabolism. As a result, MAD2L2 is an attractive target for drug development, and researchers are actively exploring its potential as a new drug or biomarker. Further research is needed to fully understand the role of MAD2L2 in cellular processes and its potential as a new drug or biomarker.

Protein Name: Mitotic Arrest Deficient 2 Like 2

Functions: Adapter protein able to interact with different proteins and involved in different biological processes (PubMed:11459825, PubMed:11459826, PubMed:17719540, PubMed:17296730, PubMed:19443654, PubMed:29656893). Mediates the interaction between the error-prone DNA polymerase zeta catalytic subunit REV3L and the inserter polymerase REV1, thereby mediating the second polymerase switching in translesion DNA synthesis (PubMed:20164194). Translesion DNA synthesis releases the replication blockade of replicative polymerases, stalled in presence of DNA lesions (PubMed:20164194). Component of the shieldin complex, which plays an important role in repair of DNA double-stranded breaks (DSBs) (PubMed:29656893). During G1 and S phase of the cell cycle, the complex functions downstream of TP53BP1 to promote non-homologous end joining (NHEJ) and suppress DNA end resection (PubMed:29656893). Mediates various NHEJ-dependent processes including immunoglobulin class-switch recombination, and fusion of unprotected telomeres (PubMed:29656893). May also regulate another aspect of cellular response to DNA damage through regulation of the JNK-mediated phosphorylation and activation of the transcriptional activator ELK1 (PubMed:17296730). Inhibits the FZR1- and probably CDC20-mediated activation of the anaphase promoting complex APC thereby regulating progression through the cell cycle (PubMed:11459825, PubMed:17719540). Regulates TCF7L2-mediated gene transcription and may play a role in epithelial-mesenchymal transdifferentiation (PubMed:19443654)

The "MAD2L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAD2L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets